CalciMedica (CALC) Current Deferred Revenue (2020 - 2021)
CalciMedica's (CALC) quarterly Current Deferred Revenue came in at $8000.0 in Q4 2021, down 70.37% YoY from $27000.0 in Q4 2020, and up 60.0% on a QoQ basis from $5000.0 in Q3 2021.
CalciMedica (CALC) Current Deferred Revenue (2020 - 2021) Analysis & Trends
CalciMedica (CALC) has 2 years of Current Deferred Revenue data on file, last reported at $8000.0 in Q4 2021.
- Quarterly Current Deferred Revenue fell 70.37% year-over-year to $8000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $8000.0 (down 70.37% YoY) and the FY2021 annual result came in at $8000.0, down 70.37% from the prior year.
- Current Deferred Revenue grew to $8000.0 in Q4 2021, from $5000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $35000.0 in Q3 2020 to a low of $5000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | CalciMedica | 10.06 Mn | -8.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 19,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Sep 30, 2020 | 35,000.00 |